Overview

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Collaborator:
Chiesi Pharmaceuticals Inc.
Treatments:
Salmeterol Xinafoate